Loading...
Loading...
Jefferies reiterates its Buy rating on Metabolix
MBLX and lowers its Price target to $9 from $13 as coming year's operations are dependent on CJ & Telles customer trade-offs.
Jefferies says, “Metabolix is at a crossroads in 2012, with Telles facing a trade-off between how fast it ramps Clinton I and margins. Metabolix has, in our view, 8-10 quarters to secure a chemical partner before facing liquidity constraints. This could be extended 4-6 quarters by shelving the biocrop platform.”
MBLX closed at $4.43 per share on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in